[go: up one dir, main page]

WO2006008005A3 - Diagnostic et traitement de maladies associees au facteur nucleaire des hepatocytes 2 (hzf2) - Google Patents

Diagnostic et traitement de maladies associees au facteur nucleaire des hepatocytes 2 (hzf2) Download PDF

Info

Publication number
WO2006008005A3
WO2006008005A3 PCT/EP2005/007449 EP2005007449W WO2006008005A3 WO 2006008005 A3 WO2006008005 A3 WO 2006008005A3 EP 2005007449 W EP2005007449 W EP 2005007449W WO 2006008005 A3 WO2006008005 A3 WO 2006008005A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
hzf2
therapeutics
diagnostics
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007449
Other languages
English (en)
Other versions
WO2006008005A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2006008005A2 publication Critical patent/WO2006008005A2/fr
Publication of WO2006008005A3 publication Critical patent/WO2006008005A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un facteur nucléaire humain des hépatocytes HZF2 qui est associé aux infections, aux troubles cardiovasculares, aux troubles du système endocrinien et hormonal, aux maladies métaboliques, aux troubles hématologiques, aux troubles musculo-squelettiques, aux troubles neurologiques, aux troubles cancéreux, aux troubles respiratoires, aux troubles urologiques. L'invention concerne également des essais destinés à l'identification de composés utiles dans le traitement ou la prévention d'infections, des troubles cardiovasculaires, aux troubles du système endocrinien et hormonal, aux maladies métaboliques, aux troubles hématologiques, aux troubles musculo-squelettiques, aux troubles neurologiques, aux troubles cancéreux, aux troubles respiratoires, aux troubles urologiques. L'invention concerne également des composés qui se lient à HZF2 et/ou qui activent ou inhibent l'activité de HZF2 ainsi que des compositions pharmaceutiques comprenant ces composés.
PCT/EP2005/007449 2004-07-23 2005-07-09 Diagnostic et traitement de maladies associees au facteur nucleaire des hepatocytes 2 (hzf2) Ceased WO2006008005A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017448 2004-07-23
EP04017448.4 2004-07-23

Publications (2)

Publication Number Publication Date
WO2006008005A2 WO2006008005A2 (fr) 2006-01-26
WO2006008005A3 true WO2006008005A3 (fr) 2006-03-30

Family

ID=35124488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007449 Ceased WO2006008005A2 (fr) 2004-07-23 2005-07-09 Diagnostic et traitement de maladies associees au facteur nucleaire des hepatocytes 2 (hzf2)

Country Status (1)

Country Link
WO (1) WO2006008005A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060860A2 (fr) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes, compositions, kits, et procedes d'identification, d'evaluation, de prevention, et de traitement du cancer de la prostate
WO2002010453A2 (fr) * 2000-07-31 2002-02-07 Gene Logic, Inc. Modelisation en toxicologie moleculaire
US20030096272A1 (en) * 2001-07-30 2003-05-22 Incyte Genomics, Inc. Genes regulated by peroxisome proliferator-activated receptor gamma agonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060860A2 (fr) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes, compositions, kits, et procedes d'identification, d'evaluation, de prevention, et de traitement du cancer de la prostate
WO2002010453A2 (fr) * 2000-07-31 2002-02-07 Gene Logic, Inc. Modelisation en toxicologie moleculaire
US20030096272A1 (en) * 2001-07-30 2003-05-22 Incyte Genomics, Inc. Genes regulated by peroxisome proliferator-activated receptor gamma agonist

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOILEAU C ET AL: "IN SEARCH OF MFS2 GENE, THE SECOND GENE IMPLICATED IN MARFAN SYNDROME", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 69, no. 4, SUPPL, October 2001 (2001-10-01), pages 617, XP009055667, ISSN: 0002-9297 *
DOWNES M ET AL: "TWO RECEPTOR INTERACTION DOMAINS IN THE COREPRESSOR, N-COR/RIP13, ARE REQUIRED FOR AN EFFICIENT INTERACTION WITH REV-ERBAALPHA AND RVR: PHYSICAL ASSOCIATION IS DEPENDENT ON THE E REGION OF THE ORPHAN RECEPTORS", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 24, no. 22, 1996, pages 4379 - 4386, XP001156849, ISSN: 0305-1048 *
DUMAS BRUNO ET AL: "A New Orphan Member of the Nuclear Hormone Receptor Superfamily Closely Related to Rev-Erb", MOLECULAR ENDOCRINOLOGY, vol. 8, no. 8, 1994, pages 996 - 1005, XP002351887, ISSN: 0888-8809 *
KOH YOUNG-SANG ET AL: "Linkage of the nuclear hormone receptor genes NR1D2, THRB, and RARB: Evidence for an ancient, large-scale duplication", GENOMICS, vol. 57, no. 2, 15 April 1999 (1999-04-15), pages 289 - 292, XP002351885, ISSN: 0888-7543 *
RANGAN V S ET AL: "PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF HEPATOCYTE NUCLEAR FACTOR 2 INVOLVED IN LIVER-SPECIFIC TRANSCRIPTION OF THE HUMAN ALPHA-1 ANTITRYPSIN GENE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 15, 1990, pages 8874 - 8879, XP002351886, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2006008005A2 (fr) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2005075665A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1)
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2004099782A3 (fr) Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2005106491A3 (fr) Diagnostic et traitement therapeutique de maladies associees a la kinase 1 regulee par serum/glucocorticoide (sgk1)
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2006008005A3 (fr) Diagnostic et traitement de maladies associees au facteur nucleaire des hepatocytes 2 (hzf2)
WO2006010514A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite
WO2004099783A3 (fr) Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g
WO2005118840A3 (fr) Elements diagnostiques therapeutiques pour des maladies associees a la kallikreine 10 (klk10)
WO2005074969A3 (fr) Diagnostics et traitements de maladies associees au recepteur nucleaire humain nr4a1 (nr4a1)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2005095984A3 (fr) Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a)
WO2005083105A3 (fr) Diagnostic et traitement de maladies associees a la glycogene synthase kinase 3 beta (gsk3b)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005040829A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 17 couple aux proteines g (gpr17)
WO2004099781A3 (fr) Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g
WO2005040822A3 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 25 couple a la proteine g (gpr25)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2005114210A8 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 3 specifique du recepteur couple a une proteine g (grk3)
WO2004104596A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a igs70 (igs70)
WO2005101009A3 (fr) Outils diagnostiques et therapeutiques pour maladies associees au recepteur 2 de tachykinine (tacr2)
WO2005059504A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g gpr34 (gpr34)
WO2005100997A3 (fr) Moyens diagnostiques et therapeutiques pour maladies associees au recepteur de tachykinine 3 (tacr3)
WO2006008008A3 (fr) Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase